TRVI logo

Trevi Therapeutics (TRVI) Company Overview

Profile

Full Name:

Trevi Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 7, 2019

Indexes:

Not included

Description:

Trevi Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic cough and other conditions. They aim to improve patients' quality of life by creating effective therapies using their expertise in drug development and clinical research.

Events Calendar

Earnings

Next earnings date:

Mar 20, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Mar 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 8, 25 D. Boral Capital
Buy
Dec 16, 24 D. Boral Capital
Buy
Dec 13, 24 HC Wainwright & Co.
Buy
Dec 12, 24 Needham
Buy
Dec 12, 24 HC Wainwright & Co.
Buy
Dec 12, 24 D. Boral Capital
Buy
Dec 4, 24 Needham
Buy
Dec 4, 24 HC Wainwright & Co.
Buy
Dec 4, 24 D. Boral Capital
Buy
Nov 8, 24 Needham
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Trevi Therapeutics to Participate in Upcoming February Investor Conferences
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
TRVI
prnewswire.comJanuary 30, 2025

NEW HAVEN, Conn. , Jan. 30, 2025 /PRNewswire/ --  Trevi Therapeutics, Inc.  (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in February.

What Makes Trevi Therapeutics (TRVI) a New Buy Stock
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
TRVI
zacks.comJanuary 8, 2025

Trevi Therapeutics (TRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
TRVI
prnewswire.comDecember 16, 2024

NEW HAVEN, Conn. , Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a price to investors of $4.00 per share, for total proceeds of $50 million, before deducting underwriting discounts and commissions and expenses payable by Trevi.

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
TRVI
prnewswire.comDecember 12, 2024

Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn. , Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in IPF patients with chronic cough, which requires no change to the current sample size for the trial (N=160).

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
TRVI
prnewswire.comDecember 3, 2024

Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:00 p .m.

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
TRVI
prnewswire.comOctober 21, 2024

Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025.

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
TRVI
prnewswire.comOctober 3, 2024

Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. , Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs.

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.
TRVI
prnewswire.comSeptember 30, 2024

NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V.

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
TRVI
prnewswire.comSeptember 26, 2024

Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn. , Sept. 26, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston, Massachusetts from October 6-9.

Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
TRVI
marketbeat.comSeptember 6, 2024

Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASDAQ: TRVI, which don't yet have any products approved by the Food and Drug Administration (FDA).

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Trevi Therapeutics?
  • Does Trevi Therapeutics pay dividends?
  • What sector is Trevi Therapeutics in?
  • What industry is Trevi Therapeutics in?
  • What country is Trevi Therapeutics based in?
  • When did Trevi Therapeutics go public?
  • Is Trevi Therapeutics in the S&P 500?
  • Is Trevi Therapeutics in the NASDAQ 100?
  • Is Trevi Therapeutics in the Dow Jones?
  • When was Trevi Therapeutics's last earnings report?
  • When does Trevi Therapeutics report earnings?
  • Should I buy Trevi Therapeutics stock now?

What is the ticker symbol for Trevi Therapeutics?

The ticker symbol for Trevi Therapeutics is NASDAQ:TRVI

Does Trevi Therapeutics pay dividends?

No, Trevi Therapeutics does not pay dividends

What sector is Trevi Therapeutics in?

Trevi Therapeutics is in the Healthcare sector

What industry is Trevi Therapeutics in?

Trevi Therapeutics is in the Biotechnology industry

What country is Trevi Therapeutics based in?

Trevi Therapeutics is headquartered in United States

When did Trevi Therapeutics go public?

Trevi Therapeutics's initial public offering (IPO) was on May 7, 2019

Is Trevi Therapeutics in the S&P 500?

No, Trevi Therapeutics is not included in the S&P 500 index

Is Trevi Therapeutics in the NASDAQ 100?

No, Trevi Therapeutics is not included in the NASDAQ 100 index

Is Trevi Therapeutics in the Dow Jones?

No, Trevi Therapeutics is not included in the Dow Jones index

When was Trevi Therapeutics's last earnings report?

Trevi Therapeutics's most recent earnings report was on Nov 6, 2024

When does Trevi Therapeutics report earnings?

The next expected earnings date for Trevi Therapeutics is Mar 20, 2025

Should I buy Trevi Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions